CGI Pharmaceuticals Inc. has built a powerful drug discovery engine that specifically addresses the unique challenges associated with kinase targets. Integrating its expertise in kinase biology with extensive chemistry and drug development capabilities, CGI is emerging as a leader in developing breakthrough kinase inhibitor therapeutics.

CGI has utilized its integrated engine to generate lead candidates from multiple chemical series, and is currently advancing these compounds into preclinical development.

Click HERE for a 2-page profile of CGI.

CGI's extensive capabilities for drug discovery and development include:

• Kinase inhibitor Focused Library
• High-throughput Accelerated Lead Optimization (HALO) Platform
• Assay Development
• Patented Chemical Genetics Technology (Analog Sensitive Kinase Alleles: ASKA)
• ADMET/PK
• In vivo Disease Models
• Clinical/Regulatory Affairs

CGI is leveraging all of these capabilities to advance its internal drug development programs in oncology and autoimmune/inflammatory disease. CGI’s unique chemical genetics technologies are also being utilized to advance the drug development programs of its partners. To date, the company has established collaborations with Serono, Pfizer, Schering, Lilly, and Affymetrix.